CJC-1295
CJC-1295 with DAC · CJC-1295 without DAC · Mod GRF 1-29 · Modified GRF 1-29 · Tetrasubstituted GRF(1-29)
Last updated
At a glance
Overview
Why CJC-1295 Earned Its Place in the Peptide Toolkit#
CJC-1295 is the workhorse GHRH analog of the peptide scene — the compound physique-focused users reach for when they want real, measurable GH-axis stimulation without the cost, logistics, or water retention of running pharma-grade rhGH. It's a tetrasubstituted analog of the first 29 amino acids of endogenous GHRH, engineered to resist enzymatic breakdown so a single injection drives a pulse of your own GH out of the pituitary — and, downstream, a sustained lift in IGF-1.
Two versions circulate, and the difference matters. CJC-1295 with DAC binds covalently to albumin and keeps IGF-1 elevated for days off a single weekly shot. CJC-1295 without DAC — functionally identical to Mod GRF 1-29 — clears in about 30 minutes and is almost always paired 1:1 with ipamorelin for pulsatile, physiologic dosing 1–3 times a day. Most of the community runs the no-DAC protocol because it preserves natural pulsatility, titrates cleanly, and keeps water retention in check.
"After a single injection, mean plasma GH concentrations increased 2- to 10-fold for 6 d or more and IGF-I levels increased 1.5- to 3-fold for 9–11 d. IGF-I levels remained above baseline for up to 28 d." — Teichman et al., JCEM (2006)
People run it for deeper sleep, visibly better skin and nails, slow-burn visceral fat loss, tendon and joint recovery, and as a cheaper way to extend the GH footprint of a low-dose rhGH protocol. It's not a mass-builder — expect subtle, cumulative recomp over 8–12 weeks, not AAS-tier gains. The rest of this page covers DAC vs no-DAC dosing, the ipamorelin stack and timing around fasted windows, cycle length, side-effect management, IGF-1 monitoring, and how CJC stacks up against rhGH when you're deciding what actually belongs in your protocol.
How CJC-1295 works
GHRH Receptor Activation and the cAMP/PKA Cascade#
CJC-1295 is a tetrasubstituted analog of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH) — the bioactive N-terminal fragment that does all the work of the native 44-AA peptide. The four substitutions (D-Ala⁸, Gln¹³, Ala¹⁵, Leu²⁷) block cleavage by DPP-IV and other serum endopeptidases that normally chew native GHRH up within minutes.
Once injected, it binds the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs — a class-B GPCR coupled to Gαs. Activation drives adenylyl cyclase → cAMP → PKA, which both synthesizes new GH and triggers pulsatile release of pre-formed GH from storage granules. This is the same receptor native GHRH uses; CJC-1295 is just a more stable ligand sitting on the pituitary side of the axis, not the hypothalamic-bypassing ghrelin-receptor side that GHRPs act on.
"Treatment with CJC-1295 resulted in normal growth rate, increased body weight, and higher serum IGF-I concentrations in GHRH knockout mice, demonstrating efficacy of the analog in restoring GH/IGF-1 axis activity." — Alba, M. et al., American Journal of Physiology-Endocrinology and Metabolism, 2006
The practical takeaway: CJC-1295 amplifies whatever GH-release machinery you already have. If your pituitary reserve is intact (and in healthy lifters under 50 it almost always is), you'll get a meaningful pulse off a modest dose.
The DAC Albumin Bioconjugate — Why Half-Life Matters#
The "DAC" (Drug Affinity Complex) version adds a maleimidopropionyl-lysine tail that covalently binds free cysteine-34 on circulating albumin, turning each peptide molecule into a long-circulating depot. This is the single feature that separates CJC-1295 DAC from its cousin Mod GRF 1-29 (no DAC), and it's the reason for the dramatic half-life gap:
| Variant | Half-life | Dosing cadence | GH pattern |
|---|---|---|---|
| Mod GRF 1-29 (no DAC) | ~30 min | 1–3× daily | Sharp pulses, physiologic |
| CJC-1295 with DAC | 5.8–8.1 days | 1–2× weekly | Amplified pulses on elevated baseline |
"The increased in vivo duration with CJC-1295 is attributed to its covalent association with endogenous albumin, extending the pharmacological activity of the peptide." — Jetté, L. et al., Endocrinology, 2005
DAC gives you convenience and sustained IGF-1 elevation; no-DAC gives you cleaner pulsatility and finer dose control. Most users in the bodybuilding and looksmaxxing community run the no-DAC + ipamorelin protocol precisely because the pulse pattern looks more like native physiology.
Pulsatile GH Release and IGF-1 Elevation#
The most important mechanistic point — and the one that separates CJC-1295 from exogenous rhGH — is that it preserves pulsatility. Even with constant circulating levels of the DAC variant, GH doesn't clamp tonically high; instead, the pituitary's natural pulse generator fires on top of an elevated baseline, and each pulse is larger in amplitude.
"Continuous stimulation with CJC-1295 increased GH pulse amplitude but did not eliminate pulsatility, suggesting that endogenous pulsatile secretion is preserved even with elevated GH levels." — Ionescu, M. & Frohman, L.A., Journal of Clinical Endocrinology & Metabolism, 2006
Downstream, those amplified GH pulses drive hepatic JAK2/STAT5 signaling and IGF-1 production. Clinical data in healthy adults:
"After a single injection, mean plasma GH concentrations increased 2- to 10-fold for 6 d or more and IGF-I levels increased 1.5- to 3-fold for 9–11 d. IGF-I levels remained above baseline for up to 28 d." — Teichman, S.L. et al., Journal of Clinical Endocrinology & Metabolism, 2006
IGF-1 is the mediator that actually does most of what users care about: satellite-cell activation (slow lean-tissue accrual), collagen and tendon remodeling, improved skin quality, and the partitioning effects that nudge nutrients toward lean tissue rather than fat storage. This is also why IGF-1 bloodwork is the single best objective marker of whether your peptide and protocol are working — you dose-respond to land in the upper-third of age-adjusted range, not above it.
Synergy with Ghrelin Mimetics (The Ipamorelin Pairing)#
GH release at the pituitary is governed by two opposing inputs: GHRH (stimulatory) and somatostatin (inhibitory), plus a third amplifier — ghrelin / GHS-R1a signaling. CJC-1295 only hits the GHRH arm. Ipamorelin, GHRP-2/6, hexarelin, and MK-677 hit the ghrelin arm. Running both simultaneously produces a GH pulse several-fold larger than either alone, because you're pushing the accelerator and releasing the brake at the same time.
This is the mechanistic reason behind the ubiquitous CJC + ipamorelin stack. Ipamorelin is the preferred ghrelin mimetic because, unlike GHRP-6 and GHRP-2, it doesn't meaningfully elevate cortisol, prolactin, or appetite — you get the synergy without the side-effect baggage.
Why Food and Insulin Blunt the Pulse#
Somatostatin tone rises sharply after a meal, particularly in response to insulin and elevated blood glucose. Since somatostatin is the physiological "off switch" at the somatotroph, injecting CJC-1295 into a fed window means you're fighting tonic inhibition — the GH pulse gets compressed or abolished regardless of how much peptide is in your system.
This is why every functional protocol specifies fasted injection windows: first thing AM, pre-workout (before intra-workout carbs), and pre-bed (3+ hours post-dinner). It's not superstition — it's the mechanistic reason underdosed-looking bloodwork often comes back from users who inject right after dinner or with their pre-workout shake. Get the timing right and you'll feel the effects (deeper sleep, vivid dreams, morning tissue fullness) within the first week; get it wrong and the peptide is largely wasted.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 100–200 mcg | Custom | Documented entry-level range |
| Mid | 200–300 mcg | Custom | Most commonly studied range |
| High | 300–500 mcg | Custom | Mod GRF 1-29 (no DAC): 100mcg SC 1–3× daily paired 1:1 with ipamorelin, timed AM fasted / pre-workout / pre-bed, 30+ min away from food. CJC-1295 DAC: 1–2mg SC weekly, or split into 2× doses per week to smooth the curve. Food and insulin blunt the pulse — always inject into a fasted window. |
Cycle length & outcomes
Documented cycle
8–12 weeks
Plateau after
16 wks
CJC-1295 is a slow-build compound — you're not chasing a weekly peak, you're nudging the GH/IGF-1 axis into a higher steady-state. That means cycle structure is about letting IGF-1 accumulate, holding it there long enough to bank the recomp benefits, and reading bloodwork to confirm the peptide is actually active. No tapering, no PCT, no HPTA drama.
How Long to Run It#
The standard block is 8–12 weeks, which tracks the published pharmacology: a single dose of CJC-1295 DAC elevates IGF-1 for 9–11 days and keeps it above baseline for up to 28 days, meaning weekly dosing stacks into a stable elevation within the first 2–3 weeks.
"After a single injection, mean plasma GH concentrations increased 2- to 10-fold for 6 d or more and IGF-I levels increased 1.5- to 3-fold for 9–11 d. IGF-I levels remained above baseline for up to 28 d." — Teichman et al., JCEM (2006)
Shorter than 8 weeks and you're barely past the IGF-1 ramp-up before stopping. Longer than 12 weeks is fine for longevity/sleep-focused users running low doses indefinitely, but physique-focused blocks see diminishing returns past the 3–4 month mark without a break.
Cycle Length by Goal#
| Goal | Protocol | Cycle Length | Dose |
|---|---|---|---|
| Sleep / recovery / longevity | CJC-1295 DAC weekly | 12+ weeks (often continuous) | 1 mg/week SC (or 500 mcg 2×/week) |
| Lean recomp / "mini GH run" | Mod GRF 1-29 + ipamorelin | 10–12 weeks | 100/100 mcg SC, 2–3×/day (AM fasted / pre-workout / pre-bed) |
| On-cycle AAS adjunct (tendon, partitioning) | Mod GRF + ipa 2×/day or DAC 1–2 mg/week | Full AAS cycle (8–16 weeks) | 100/100 mcg pulses or 1–2 mg DAC weekly |
| Pre-contest / cutting with rhGH | rhGH AM + Mod GRF/ipa PM | 8–12 weeks | 2 IU rhGH AM + 100/100 mcg pre-bed |
| Beginner intro to GH-axis | Mod GRF + ipamorelin, pre-bed only | 8–12 weeks | 100/100 mcg SC nightly |
Onset Timing — What to Expect and When#
- Week 1: Deeper, more vivid sleep within the first few injections. This is the earliest reliable signal the peptide is pharmacologically active. Mild injection-site redness (DAC more than no-DAC) and transient post-injection flushing at higher doses are normal.
- Weeks 2–3: IGF-1 climbs to new steady-state. Morning fasted puffiness / ring-tightness starts becoming a useful dose-feedback marker — a little is expected, a lot means back off.
- Weeks 3–6: Soft-tissue recovery noticeably faster, skin and nail quality improve, slow visceral fat reduction begins. This is when you'd pull mid-cycle bloodwork.
- Weeks 6–12: Body-recomp effects compound. Lean-tissue accrual is modest (~0.1–0.15 lb/week) — this is not an AAS substitute. Fat loss trends ~0.15–0.2 lb/week on top of dietary deficit.
Loading and Tapering#
There is no loading phase and no taper. The DAC's week-long half-life handles "ramping" automatically — weekly dosing builds to steady state within ~3 weeks on its own. Stopping cold turkey at the end of the block produces no rebound, no withdrawal, and no HPTA consequence; IGF-1 simply decays back toward baseline over 2–4 weeks as the albumin-bound depot clears.
"The increased in vivo duration with CJC-1295 is attributed to its covalent association with endogenous albumin, extending the pharmacological activity of the peptide." — Jetté et al., Endocrinology (2005)
For the no-DAC / Mod GRF protocol, the half-life is ~30 minutes, so every injection is effectively its own pulse — you can start, stop, skip, or rotate dosing windows without disrupting anything.
Dose Timing Within the Day#
For no-DAC protocols, timing matters a lot. GHRH-driven pulses are blunted by somatostatin (rises with feeding) and insulin (post-carb spike), so injections go into fasted or semi-fasted windows:
- AM dose: immediately on waking, 30+ min before first meal.
- Pre-workout dose: 30–45 min before lifting, on an empty stomach if possible.
- Pre-bed dose: at least 90 min post-dinner, ideally right before lights-out to stack with the natural slow-wave-sleep GH pulse.
For DAC, timing is largely irrelevant — the albumin depot flattens the pulse anyway. Most users inject on the same day each week for routine.
Pulsatility Preservation#
One of the cleaner findings with CJC-1295 is that endogenous pulsing survives even under chronic elevation — so you don't shut down the axis the way supraphysiologic rhGH does:
"Continuous stimulation with CJC-1295 increased GH pulse amplitude but did not eliminate pulsatility, suggesting that endogenous pulsatile secretion is preserved even with elevated GH levels." — Ionescu & Frohman, JCEM (2006)
This is why there's no "recovery" period needed between cycles — the pituitary isn't being suppressed, it's being amplified.
Bloodwork Cadence#
| Timepoint | What to Check |
|---|---|
| Baseline (week 0) | IGF-1, fasting glucose, HbA1c |
| Week 6–8 | IGF-1 (primary — confirms the vial is active and dose is dialed), fasting glucose |
| End of cycle (week 10–12) | IGF-1, fasting glucose, HbA1c |
| If running continuously | Repeat IGF-1 + fasting glucose every 8–12 weeks |
Target IGF-1 in the upper third of age-adjusted range — not supra-physiologic. If you're still mid-range at week 6 with adherent dosing, your vial is likely underdosed or degraded; reconstituted peptide loses potency past ~30 days at 4°C. Fasting glucose creeping up more than ~10 mg/dL over baseline is a signal to drop dose — GH is counter-regulatory to insulin, and the DAC version is more prone to this than pulsatile no-DAC protocols.
Between Cycles#
For physique blocks, 4 weeks off between 8–12 week runs is standard and more than sufficient — IGF-1 clears well before then. For sleep/longevity users on 1 mg/week DAC, indefinite continuous use is common practice; the rationale for breaks here is less about receptor desensitization and more about giving bloodwork a clean baseline window twice a year.
Body Transformation Preview
Lean Mass Gain
1.5 lbs
1.1–1.8 lbs range
Fat Loss
1.9 lbs
1.5–2.4 lbs range
Fat Loss by Week
Risks & mistakes
Common (most users)#
- Injection-site reactions — redness, itching, small wheal, particularly with the DAC version. Rotate sites between lower abdomen, love handles, and outer thigh. Usually fades over the first 2–3 weeks of use.
- Flushing / warmth / lightheadedness post-injection — classic GHRH-mediated vasodilation, peaks 5–15 min after the shot and resolves within an hour. Inject seated, split the dose if it's pronounced at 100 mcg.
- Transient headache — same vasodilatory mechanism. Hydrate; if it persists past the first few doses, drop the per-pulse dose to 75 mcg.
- Vivid dreams / deeper sleep — not really an adverse effect but worth naming. Comes from the nighttime GH pulse amplifying slow-wave sleep. Inject pre-bed on an empty stomach to lean into it.
- Mild morning puffiness / ring-tightness — early sign the GH pulse is doing its job. Mild puffiness is expected; if it's visibly affecting the face or hands past week 2, the dose is too high.
- Hunger bump — CJC itself is appetite-neutral; if you're ravenous, that's the GHRP side of the stack (especially GHRP-6). Switch to ipamorelin if it's disrupting your cut.
Uncommon (dose-dependent or individual)#
- Persistent water retention — more common with DAC at ≥2 mg/week than with pulsatile Mod GRF protocols. Drop the weekly dose or split it into two smaller injections. If it doesn't resolve, move to no-DAC.
- Numbness, tingling, or carpal tunnel–type symptoms — the textbook GH-excess signal. Cut the dose immediately; these fully reverse within 1–2 weeks off.
- Joint aches / stiffness — usually means IGF-1 is climbing fast. Pull back 25–50% and recheck IGF-1 at 6 weeks.
- Fasting glucose creep / HbA1c drift upward — GH is counter-regulatory to insulin. At physique-realistic doses the effect is modest, but check fasting glucose and HbA1c every 8–12 weeks on chronic protocols. If fasting glucose is trending past 100 mg/dL, reduce dose or add berberine/metformin.
- Elevated IGF-1 above age-adjusted upper-third — dose-respond down. Target upper-quartile of age-adjusted range, not supraphysiologic.
- Loss of GH pulsatility on high-dose DAC — running DAC at 3+ mg/week tonically saturates the GHRH receptor and erases pulses, which is exactly what you don't want.
"Continuous stimulation with CJC-1295 increased GH pulse amplitude but did not eliminate pulsatility, suggesting that endogenous pulsatile secretion is preserved even with elevated GH levels." — Ionescu & Frohman, JCEM (2006)
At community-standard doses, pulsatility holds. It's dose abuse that breaks it.
Rare but serious#
- Worsening of pre-existing insulin resistance or frank hyperglycemia — stop if fasting glucose climbs into the diabetic range or HbA1c breaks 6.0%.
- Acromegalic features from chronic supraphysiologic IGF-1 — brow, jaw, hand, and foot changes over months to years of running high doses without bloodwork. Almost exclusively a problem in users who stack DAC + MK-677 + rhGH and never test. Don't be that guy.
- Cardiac symptoms — community lore around the late-2000s French DAC reports is unresolved; the causal link was never established and millions of doses have been run since without a consistent signal. Still, any new chest pain, persistent tachycardia, or exercise-intolerance warrants stopping and working up.
- Accelerated tumor growth — biologically plausible given IGF-1 is mitogenic. Any unexplained lump, persistent lymphadenopathy, or GI/urinary symptom → stop and get worked up before resuming.
Hard contraindications#
- Active malignancy or history of cancer — elevating IGF-1 plausibly supports tumor growth. Do not run this with unresolved oncologic history.
- Active diabetic retinopathy or uncontrolled type 2 diabetes — GH worsens both; the retinopathy risk is not negotiable.
- Untreated severe sleep apnea — GH-axis stimulation worsens soft-tissue airway obstruction. Treat the apnea first, then reconsider.
- Pregnancy — no safety data, and the GH/IGF-1 axis is not something to perturb during gestation.
- Planned major surgery within 2 weeks — hold dosing; let IGF-1 normalize before going under.
Gender-specific & PCT notes#
Works equivalently in men and women at the same absolute doses. Women often prefer the no-DAC (Mod GRF + ipamorelin) protocol because water retention and puffiness are easier to titrate pulse-by-pulse than with a week-long DAC depot. No virilization risk — this is not an androgen.
No PCT required. The GHRH axis is independent of the HPTA; CJC-1295 does not suppress LH, FSH, or testosterone, so it can be run continuously, during cruise, or alongside AAS cycles without affecting recovery protocols. The one piece of post-cycle bloodwork that matters here is IGF-1 + fasting glucose + HbA1c — not a hormone panel.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.18 | ×1.22 | ×1.28 | |
| synergistic | ×1.22 | ×1.15 | ×1.25 | |
| synergistic | ×1.18 | ×1.15 | ×1.20 | |
| synergistic | ×1.17 | ×1.08 | ×1.18 |
Featured in stacks1 curated protocol include CJC-1295
FAQ — CJC-1295
Where to buy
Swiss Chems
Affiliate link — we may earn a commission at no cost to you.
- Buy CJC-1295 without DAC 2 mg - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy CJC-1295
- Buy CJC-1295 with DAC, 2mg - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy CJC-1295
Real Peptides
Affiliate link — we may earn a commission at no cost to you.
- CJC 1295 (no dac)Buy CJC-1295
Research & citations
5 studies cited on this page.
Conclusion
CJC-1295 is a go-to GH secretagogue for users who want steady, reliable IGF-1 elevation and real-world sleep and recovery benefits without jumping straight to exogenous GH.
Key takeaways:
- Standard dose: Mod GRF 1-29 (no DAC) 100 µg + ipamorelin 100 µg, 1–3× daily, always fasted
- CJC-1295 DAC: 1–2 mg SC weekly, or split into 2×/week for smoother GH/IGF-1 profile
- Typical cycle: 8–12 weeks on, 4 weeks off; can be run longer at lower doses for sleep, longevity, or recovery
- Stack with ipamorelin or other GHRPs for amplified GH pulses — the synergy is why this stack dominates
- Main benefits: improved deep sleep, better connective tissue/joint recovery, subtle fat loss, and IGF-1 in the high-normal range
- Watch for dose-dependent water retention, especially with DAC; always inject away from meals to avoid pulse blunting
If you want to tap the GH/IGF-1 axis for physique, health, or recovery, a CJC-1295 combo protocol is simple, effective, and easy to titrate — the community's favorite for good reason.